US · Healthcare · Biotechnology
EPS came in at -1.78 against a street estimate of -0.71 — a miss of 150.7%.
Analysts rate Seaport Therapeutics, Inc. Common Stock a strong buy (7 buy, 1 hold, 0 sell out of 8) with an average price target of $38.29.
| Fund | Stake |
|---|---|
| ARCH VENTURE CORP | 11.76% |
| General Atlantic Llc | 11.40% |
| Sofinnova Ventures | 6.66% |
| The Goldman Sachs Group Inc | 4.07% |
| TRV GP VI, LLC | 3.85% |
| Canada Pension Plan Investment Board | 3.69% |
| JPMorgan Chase & Co | 3.39% |
| Foresite Capital Management VI LLC | 3.32% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 SEAPORT THERAPEUTICS, INC. - 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Cash and investments: $427.3 million (cash $64.2M + short-term investments $2 | 2026-08-03 |
| Results announced · Q3 2026 SEAPORT THERAPEUTICS Q2 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Cash, cash equivalents, and investments: $427.3 million as of June 30, 202 | 2026-08-03 |
| Quarterly report · Q1 2026 SEAPORT THERAPEUTICS, INC. - Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash position: $52.9 million in cash and cash equivalents as of March 31, 2026 | 2026-06-08 |
| Results announced · Q2 2026 SEAPORT THERAPEUTICS Q1 2026 FINANCIAL RESULTS SUMMARY HEADLINE NUMBERS • Net loss for Q1 2026: $25.4 million (vs. $13.1 million in Q1 2025) • Net l | 2026-06-08 |
| Charter / bylaws change · Q2 2026 SEAPORT THERAPEUTICS, INC. - 8-K SUMMARY HEADLINE NUMBERS • Company: Seaport Therapeutics, Inc. (ticker: SPTX, Nasdaq Global Select Market) • Report | 2026-05-04 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Seaport Therapeutics, Inc. Common Stock — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.